Cargando…
A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia
A 67-year-old male, with a known diagnosis of myelodysplastic syndromes with multilineage dysplasia (MDS-MLD) was admitted to our hospital with a primary complaint of subcutaneous bleeding in his left thigh. Laboratory data showed anaemia and prolongation of activated partial thromboplastin time (85...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6415290/ https://www.ncbi.nlm.nih.gov/pubmed/30937199 http://dx.doi.org/10.1155/2019/8612031 |
_version_ | 1783403156971978752 |
---|---|
author | Araki, Takeshi Ohata, Shinya Okamoto, Kohei Morimoto, Kazuhide Hiraishi, Mana Yamada, Shinichiro Mizuno, Ishikazu Sugimoto, Takeshi |
author_facet | Araki, Takeshi Ohata, Shinya Okamoto, Kohei Morimoto, Kazuhide Hiraishi, Mana Yamada, Shinichiro Mizuno, Ishikazu Sugimoto, Takeshi |
author_sort | Araki, Takeshi |
collection | PubMed |
description | A 67-year-old male, with a known diagnosis of myelodysplastic syndromes with multilineage dysplasia (MDS-MLD) was admitted to our hospital with a primary complaint of subcutaneous bleeding in his left thigh. Laboratory data showed anaemia and prolongation of activated partial thromboplastin time (85.8 s, normal range 24–39 s) without thrombocytopenia. Coagulation factor VIII (FVIII) activity was less than 1% (normal range 60–150%), and a FVIII inhibitor was identified and quantified at 166 BU/mL to indicate a diagnosis of acquired haemophilia A (AHA). A recent, but sustained circulating monocytosis (>1 × 10(9)/L) was observed, which combined with elevated numbers of neutrophil and monocytic cells in the marrow, suggested evolution of MDS-MLD to chronic myelomonocytic leukaemia (CMML), coinciding with AHA. Further analysis revealed a karyotype of 46, XY, i(14) (q10), which was the same abnormality previously identified in the patient. To treat bleeding caused by AHA, steroid and activated prothrombin complex concentrate were administered. Azacitidine (AZA) was used to treat CMML. During the clinical course, bleeding partially improved; however, subsequent acute myocardial infarction occurred on day 87. Worsening bone marrow failure was observed 4 months after the original admission, despite administration of AZA therapy, and the patient died due to bleeding from AHA. This case suggests that the evolution of MDS to CMML status can be associated with AHA conferring a bleeding tendency. |
format | Online Article Text |
id | pubmed-6415290 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-64152902019-04-01 A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia Araki, Takeshi Ohata, Shinya Okamoto, Kohei Morimoto, Kazuhide Hiraishi, Mana Yamada, Shinichiro Mizuno, Ishikazu Sugimoto, Takeshi Case Rep Hematol Case Report A 67-year-old male, with a known diagnosis of myelodysplastic syndromes with multilineage dysplasia (MDS-MLD) was admitted to our hospital with a primary complaint of subcutaneous bleeding in his left thigh. Laboratory data showed anaemia and prolongation of activated partial thromboplastin time (85.8 s, normal range 24–39 s) without thrombocytopenia. Coagulation factor VIII (FVIII) activity was less than 1% (normal range 60–150%), and a FVIII inhibitor was identified and quantified at 166 BU/mL to indicate a diagnosis of acquired haemophilia A (AHA). A recent, but sustained circulating monocytosis (>1 × 10(9)/L) was observed, which combined with elevated numbers of neutrophil and monocytic cells in the marrow, suggested evolution of MDS-MLD to chronic myelomonocytic leukaemia (CMML), coinciding with AHA. Further analysis revealed a karyotype of 46, XY, i(14) (q10), which was the same abnormality previously identified in the patient. To treat bleeding caused by AHA, steroid and activated prothrombin complex concentrate were administered. Azacitidine (AZA) was used to treat CMML. During the clinical course, bleeding partially improved; however, subsequent acute myocardial infarction occurred on day 87. Worsening bone marrow failure was observed 4 months after the original admission, despite administration of AZA therapy, and the patient died due to bleeding from AHA. This case suggests that the evolution of MDS to CMML status can be associated with AHA conferring a bleeding tendency. Hindawi 2019-02-27 /pmc/articles/PMC6415290/ /pubmed/30937199 http://dx.doi.org/10.1155/2019/8612031 Text en Copyright © 2019 Takeshi Araki et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Araki, Takeshi Ohata, Shinya Okamoto, Kohei Morimoto, Kazuhide Hiraishi, Mana Yamada, Shinichiro Mizuno, Ishikazu Sugimoto, Takeshi A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia |
title | A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia |
title_full | A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia |
title_fullStr | A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia |
title_full_unstemmed | A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia |
title_short | A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia |
title_sort | case of acquired haemophilia a in a patient with chronic myelomonocytic leukaemia |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6415290/ https://www.ncbi.nlm.nih.gov/pubmed/30937199 http://dx.doi.org/10.1155/2019/8612031 |
work_keys_str_mv | AT arakitakeshi acaseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia AT ohatashinya acaseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia AT okamotokohei acaseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia AT morimotokazuhide acaseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia AT hiraishimana acaseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia AT yamadashinichiro acaseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia AT mizunoishikazu acaseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia AT sugimototakeshi acaseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia AT arakitakeshi caseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia AT ohatashinya caseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia AT okamotokohei caseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia AT morimotokazuhide caseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia AT hiraishimana caseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia AT yamadashinichiro caseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia AT mizunoishikazu caseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia AT sugimototakeshi caseofacquiredhaemophiliaainapatientwithchronicmyelomonocyticleukaemia |